

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

INNOVATIVE DRUG “SYHA1811 TABLETS” OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that “SYHA1811 Tablets” (the “**Product**”), a class 1 innovative anti-tumor drug with its exclusive development and commercialization rights in China licensed to the Group, has obtained approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

The Product is a BTK inhibitor jointly developed by Shanghai Runshi Pharmaceutical Technology Co., Ltd* (上海潤石醫藥科技有限公司), a non-wholly owned subsidiary of the Company, and Shanghai Institute of Materia Medica of the Chinese Academy of Sciences. The clinical indication for this approval is relapsed or refractory B-cell lymphoma, including but not limited to mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), waldenstrom’s macroglobulinemia (WM), marginal zone lymphoma (MZL), follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). The pre-clinical studies have shown that as a selective BTK inhibitor, the Product has a better efficacy in the treatment of B-cell malignancies and good safety as well as pharmacokinetic characteristics, providing a promising prospect of demonstrating good anti-tumor efficacy in the clinical trials.

Given the favorable results of the non-clinical studies, the Group will endeavor to push forward the clinical trials of the Product and strive to launch the Product as soon as possible.

* *For identification purposes only*

By order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 20 May 2021

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors.